38.90 -0.13 (-0.33%)
After hours: 7:59PM EDT
|Bid||38.94 x 3200|
|Ask||38.98 x 3000|
|Day's range||38.75 - 39.24|
|52-week range||29.99 - 43.08|
|Beta (5Y monthly)||0.65|
|PE ratio (TTM)||22.86|
|Earnings date||04 May 2021|
|Forward dividend & yield||1.56 (4.01%)|
|Ex-dividend date||28 Jan 2021|
|1y target est||40.69|
European regulators greenlight J&J COVID-19 vaccine, but also warn blood clots will be listed as potential side effect.
Emergent (EBS) halts manufacturing at Bayview facility as the FDA initiates investigation of the error that led to manufacturing of faulty doses of J&J's COVID-19 vaccine.
The European Commission exercises its option to purchase an additional 100 million doses of Pfizer (PFE)/ BioNTech's COVID-19 vaccine, Comirnaty, for EU member states.